Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy

RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI-by-design mobile networks, today announced a strong leadership team to accelerate its vision for telco-first, cloud-native, AI-by-design networks. This transformation follows the company's recent recapitalization and aligns with a refreshed product strategy focused on mobile core, AI-enabled automation, and cloud-native platforms. New […]

FutureFuel Announces Director and Chairman of the Board Appointment

(NYSE:FF), COMPANY CONTACT:FutureFuel Corp.Roeland Polet(314) 854-8352www.futurefuelcorporation.com BATESVILLE, Ark., Dec. 08, 2025 (GLOBE NEWSWIRE) — FutureFuel Corp. (NYSE: FF) (“FutureFuel” or the “Company”), a manufacturer of custom and performance chemicals and biofuels, announced today that effective as of December 4, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of FutureFuel Corp. (the “Company”) increased

Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees

(NasdaqGM:NEUP), Company Urges Shareholders to Follow ISS' Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders

SPX Technologies to Acquire Crawford United

(Other OTC:CRAWA),(OTC US:CRAWA), CHARLOTTE, N.C. and CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) — SPX Technologies, Inc. (NYSE:SPXC) (“SPX” or the “Company”) and Crawford United Corporation (OTC: CRAWA) (“Crawford United”) announced today that they have entered into a definitive agreement for SPX to acquire Crawford United, a Cleveland-based holding company with a broad portfolio of highly

Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies

(NASDAQ:PRAX), Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor seizure-free days (p = 0.0340), broad and clinically meaningful functional improvements (p less-than or equal to 0.002) Patients in the RADIANT study of vormatrigine showed rapid, consistent and durable improvement in seizure

EBZT Announces Sports Edge AI Development for Polymarket Sports Prediction Markets

(PinkSheets:EBZT),(Pinksheets:EBZT), Jacksonville, Florida, Dec. 08, 2025 (GLOBE NEWSWIRE) — Everything Blockchain Inc. (OTC: EBZT) (“EBZT” or the “Company”), a public AI development lab, today announced Sports Edge AI, a new in-house trading system that uses artificial intelligence to look for pricing edges in sports prediction markets, mainly on Polymarket. By moving into this fast-growing area

Rocket Doctor AI, Health Cities and CAN Health Network Partner to Advance AI-Powered Clinical Decision Support in Alberta

(CNSX:AIDR),(OTC US:AIRDF),(Other OTC:AIRDF),(Boerse Frankfurt – Freiverkehr:939),(CNSX:AIDR.CN),(Boerse Frankfurt – Freiverkehr:939.F), Rocket Doctor AI joins forces with the CAN Health Network to deliver an AI-powered Clinical Decision Support System (CDSS) in collaboration with Health Cities Alberta. Initial rollout will take place at up to four primary care sites serving up to 20 physicians, running from December 2025

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs

(NasdaqGM:FATE), FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated First ex-U.S. SLE patient treated with FT819 expands enrollment capacity and supports unique ability of FT819 for broad, on-demand patient accessibility Preclinical studies show FT836 chimeric antigen

CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia

(NASDAQ:GDTC), SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today announced that it

NEXE Innovations Sees Growing Repeat Demand for Its Compostable Coffee Pods; ecoBeans Orders 70,000 Pods, Its Largest Order to Date

(TSX-V:NEXE),(OTC US:NEXNF),(Other OTC:NEXNF),(Frankfurt:NX5), WINDSOR, Ontario, Dec. 08, 2025 (GLOBE NEWSWIRE) — NEXE Innovations Inc. (“NEXE”, the “Company”, “we”, “us” or “our”) (TSX.V: NEXE) (Frankfurt: NX5) (OTC: NEXNF), a compostable and innovative materials company, is pleased to announce it has received a purchase order for 70,000 BPI-certified compostable coffee pods from ecoBeans Coffee Inc. (“ecoBeans”), its

Scroll to Top